- Home
- NAKA vs EDIT Comparison
NAKA vs EDIT Comparison
Compare NAKA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAKA | EDIT |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | 61 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 206.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NAKA | EDIT |
|---|---|---|
| Price | $0.26 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.25 | ★ $4.92 |
| AVG Volume (30 Days) | ★ 4.5M | 1.7M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,517.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $0.23 | $0.91 |
| 52 Week High | $29.50 | $4.54 |
Technical Indicators
Market Signals| Indicator | NAKA | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 61.33 |
| Support Level | $0.24 | $2.42 |
| Resistance Level | $0.29 | $2.76 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 56.10 | 75.13 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.